<DOC>
	<DOC>NCT00049829</DOC>
	<brief_summary>HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.</brief_summary>
	<brief_title>HORIZON-PFT: Pivotal Fracture Trial</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>Female, 6589 years old No history of severe liver, kidney or eye disease Current bisphosphonate users such as Aredia® (pamidronate), Didronel® (etidronate), Fosamax® (alendronate), Actonel® (risedronate), Skelid® (tiludronate) Using hip protectors Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Bisphosphonate,BMD,Height loss, Hip protectors,HRT,</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>